Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston

Company Overview - Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing medications for skin diseases that require medical interventions [3] - The company's product YCANTH (VP-102) is the first and only FDA-approved treatment for molluscum contagiosum, a viral skin infection affecting approximately 6 million people in the U.S., primarily children [3] - YCANTH (VP-102) is also being developed for treating common warts and external genital warts, addressing significant unmet needs in medical dermatology [3] - Verrica is developing VP-103, a second cantharidin-based product candidate for plantar warts [3] - The company has a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma [3] Upcoming Event - Jayson Rieger, PhD, MBA, President and CEO of Verrica, will participate in a fireside chat at the TD Cowen 45 Annual Health Care Conference in Boston on March 3, 2025, at 2:30 pm ET [1][2] - Participants can access a live webcast of the event through a link provided, with a replay available for 90 days post-event [2]